JP2014526435A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526435A5
JP2014526435A5 JP2014511630A JP2014511630A JP2014526435A5 JP 2014526435 A5 JP2014526435 A5 JP 2014526435A5 JP 2014511630 A JP2014511630 A JP 2014511630A JP 2014511630 A JP2014511630 A JP 2014511630A JP 2014526435 A5 JP2014526435 A5 JP 2014526435A5
Authority
JP
Japan
Prior art keywords
group
alkyl group
lower alkyl
disorder
lower alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511630A
Other languages
English (en)
Japanese (ja)
Other versions
JP6193848B2 (ja
JP2014526435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2012/073556 external-priority patent/WO2013035892A1/en
Publication of JP2014526435A publication Critical patent/JP2014526435A/ja
Publication of JP2014526435A5 publication Critical patent/JP2014526435A5/ja
Application granted granted Critical
Publication of JP6193848B2 publication Critical patent/JP6193848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511630A 2011-09-08 2012-09-07 複素環化合物及びその用途 Active JP6193848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532393P 2011-09-08 2011-09-08
US61/532,393 2011-09-08
PCT/JP2012/073556 WO2013035892A1 (en) 2011-09-08 2012-09-07 Piperazine- substituted benzothiophene derivatives as antipsychotic agents

Publications (3)

Publication Number Publication Date
JP2014526435A JP2014526435A (ja) 2014-10-06
JP2014526435A5 true JP2014526435A5 (enExample) 2015-10-29
JP6193848B2 JP6193848B2 (ja) 2017-09-06

Family

ID=46940565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511630A Active JP6193848B2 (ja) 2011-09-08 2012-09-07 複素環化合物及びその用途

Country Status (31)

Country Link
US (10) US9260420B2 (enExample)
EP (1) EP2753617B9 (enExample)
JP (1) JP6193848B2 (enExample)
KR (1) KR101998441B1 (enExample)
CN (1) CN103781783B (enExample)
AR (1) AR087809A1 (enExample)
AU (1) AU2012305212B2 (enExample)
BR (1) BR112014005235B1 (enExample)
CA (1) CA2847339C (enExample)
CO (1) CO6930362A2 (enExample)
CY (1) CY1118753T1 (enExample)
DK (1) DK2753617T3 (enExample)
EA (1) EA028160B1 (enExample)
ES (1) ES2572934T3 (enExample)
HR (1) HRP20160824T2 (enExample)
HU (1) HUE027746T2 (enExample)
IL (1) IL231116B (enExample)
JO (1) JO3227B1 (enExample)
MX (1) MX359515B (enExample)
MY (1) MY196864A (enExample)
PH (1) PH12014500496A1 (enExample)
PL (1) PL2753617T3 (enExample)
PT (1) PT2753617T (enExample)
RS (1) RS54894B9 (enExample)
SG (2) SG10201601731RA (enExample)
SI (1) SI2753617T1 (enExample)
SM (1) SMT201600205B (enExample)
TW (1) TWI568728B (enExample)
UA (1) UA112993C2 (enExample)
WO (1) WO2013035892A1 (enExample)
ZA (1) ZA201401433B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β-環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP2014196292A (ja) * 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US10583840B2 (en) * 2016-09-08 2020-03-10 Ford Motor Company Methods and apparatus to monitor an activity level of a driver
CN106699745A (zh) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US20180265472A1 (en) * 2017-03-17 2018-09-20 Scinopharm Taiwan, Ltd. Process for preparing aripiprazole lauroxil and intermediates thereof
CN107628999B (zh) * 2017-10-25 2019-07-02 苏州华健瑞达医药技术有限公司 阿立哌唑十二烷酸酯的制备方法
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
HUE065684T2 (hu) * 2019-01-11 2024-06-28 Alar Pharmaceuticals Inc Ketamin-pamoát és alkalmazása
TW202216676A (zh) * 2020-07-06 2022-05-01 美商塔朵根公司 用於心理疾病或心理強化的有益苯并噻吩組合物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
CN114044772A (zh) * 2021-11-29 2022-02-15 浙江国邦药业有限公司 一种依匹哌唑合成方法及其中间体
CN116407539B (zh) * 2021-12-30 2025-01-10 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯的用途
CN116410186B (zh) * 2021-12-30 2025-03-04 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯及其制备方法
WO2023186023A1 (zh) * 2022-03-30 2023-10-05 苏州旺山旺水生物医药股份有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
TW202438064A (zh) * 2023-02-27 2024-10-01 日商大塚製藥股份有限公司 用於治療心理疾病之經哌𠯤取代之苯并噻吩
AU2024266462A1 (en) * 2023-05-02 2025-08-28 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200500342A1 (ru) 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Гетероциклические замещённые пиперазины для лечения шизофрении
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050254575A1 (en) 2004-05-12 2005-11-17 Nokia Corporation Multiple interoperability points for scalable media coding and transmission
DE102004031052A1 (de) 2004-06-25 2006-01-12 Bühler AG System und Verfahren zur Mahlgut-Charakterisierung in einem Walzenstuhl
US7802705B2 (en) 2004-07-29 2010-09-28 Magie Pression Co., Ltd. Method for forming pleat on fabric composed of polylactic acid yarn, and pleated fabric
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2006111246A1 (de) 2005-04-18 2006-10-26 Loi Thermprocess Gmbh Industrieofen
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP5732453B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルapiローディングプロドラッグ
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Similar Documents

Publication Publication Date Title
RU2012134306A (ru) Азотосодержащие производные гетероарилов
CN109963854A (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
HRP20160824T2 (hr) Derivati benzotiofena supstituirani piperazinom kao antipsihotički agensi
JP2019532079A5 (enExample)
JP2017533968A5 (enExample)
JP2012506381A5 (enExample)
JP2008540637A5 (enExample)
JP2005510473A5 (enExample)
JP2020502092A5 (enExample)
RU2008148902A (ru) Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3)
NZ630260A (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
RU2015143466A (ru) Нейроактивные стероиды и способы их применения
NZ592961A (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
JP2016505637A5 (enExample)
JP2016503797A5 (enExample)
JP2012097115A5 (enExample)
JP2013540755A5 (enExample)
JP2009542638A5 (enExample)
JP2019505595A5 (enExample)
JP2019537592A5 (enExample)
JP2009513575A5 (enExample)
RU2011136821A (ru) Дигидрохинолиноновые производные
JP2020503246A5 (enExample)
RU2015101102A (ru) Гетероароматическое метильное производное циклического амина
RU2013125338A (ru) Производные триазола в качестве лигандов рецепторов гамк